Home

European Society of Hypertension (ESH), the leading hypertension (HTN) society in Europe, presented an updated position paper on renal denervation (RDN) during the eighth pre-ESH congress satellite symposium (10–11 September; Athens, Greece). The paper was recently published in the September issue of the Journal of Hypertension.

This position paper written by an ESH expert working group confirms that RDN is considered a safe endovascular procedure without significant short-term or long-term adverse effects based on data available up to three years.

“In light of the recent publication of several second-generation sham-controlled clinical trials, we thought it was important to provide an updated position paper on RDN and its role in treating uncontrolled hypertension,” said Roland Schmieder, professor of Internal Medicine, Nephrology and Hypertension at the University Hospital Erlangen, Germany and chairman of the ESH working group on interventional treatment of hypertension.

RDN is a minimally invasive procedure intended to regulate overactivity of nerves that lead to and from the kidney, which play an important role in controlling blood pressure.

In recent sham-controlled randomised trials and registries, clinically favourable effects of RDN have been consistently demonstrated across a wide spectrum of patients with uncontrolled HTN, in the absence and presence of prescribed anti-hypertensive medications.

“RDN represents an evidence-based option to treat HTN, in addition to lifestyle changes and blood pressure lowering drugs. RDN expands therapeutic options to address the first objective of HTN treatment, to effectively reduce elevated blood pressure and achieve blood pressure targets,” said Konstantinos Tsioufis, MD, professor of Cardiology at the University of Athens, Athens, Greece and immediate past president of ESH. “Heightened cardiovascular risk such as evident organ damage or established disease like coronary artery disease or heart failure might be pointing towards treatment priority with RDN in hypertension. Additionally, patients who are unable or unwilling to take medication might be another RDN group, especially in the first stages of the hypertensive disease.”

Arterial hypertension constitutes the most prevalent and important risk factor for cardiovascular morbidity and mortality globally despite the availability of pharmacological treatments. In addition, approximately half of individuals with hypertension do not meet guideline-directed blood pressure (BP) goals.

“Many patients with uncontrolled hypertension struggle to adhere to lifelong drug therapy for a variety of reasons and may look to other options that complement traditional treatments,” said Reinhold Kreutz, professor of Clinical Pharmacology and Hypertension at the Charité Universitaetsmedizin in Berlin, Germany and president of ESH. “We believe this advance could help clinicians work with patients to better manage their high blood pressure.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua google bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua twitter bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua MySpace bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua LinkedIn bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua stumbleupon bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua icio bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua digg bài: ESH position paper highlights renal denervation as a third option for hypertension management

Chia sẽ qua yahoo bài: ESH position paper highlights renal denervation as a third option for hypertension management

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.